CREATE Medicines Secures $122 Million in Series B Financing for CAR-T Therapy Advancement

CREATE Medicines, a pioneering clinical-stage biotechnology firm, has announced its successful closure of a $122 million Series B funding round. The financing, co-led by existing investors such as Newpath Partners, ARCH Venture Partners, and Hatteras Venture Partners, aims to propel the advancement of CREATE's innovative pipeline focused on autoimmune diseases and oncology. With additional participation from Alexandria Venture Investments and others, this funding reflects strong conviction in CREATE's ongoing clinical trajectory.

The funds raised will be pivotal in moving CREATE's next-generation CD19 targeted in vivo CAR-T therapy for autoimmune ailments into clinical settings, alongside expanding its dual CAR CD19 x BCMA program. The company has already made significant strides, having administered treatment to over 50 patients, representing the largest clinical dataset in the field. This data not only lays the foundation for future development but also enhances CREATE's understanding of the therapeutic landscape in these challenging domains.

CREATE's proprietary mRNA-LNP platform has been a game changer in the field of immune programming. By directly engaging immune cells within the patient's body, the company has established a rapid and efficient product development cycle that compresses timelines from concept to clinic.

In autoimmune diseases, the leading program, CRT-402, showcases promising results, demonstrating extensive B cell depletion in non-human primate studies. This program has the potential to facilitate immune reset through a flexible repeat dosing strategy. Furthermore, CREATE is advancing a dual CAR target—focusing on CD19 and BCMA—widely regarded as a strategic move to tackle stubborn types of autoimmune conditions that have proven resistant to other therapies.

On the oncology front, CREATE is dedicated to developing therapeutic candidates aimed at substantial unmet needs. Early clinical insights from the MT-303 program targeting frontline hepatocellular carcinoma reveal a compelling response profile, suggesting transformative potential for patients stricken by this aggressive cancer type.

The integrated platform employed by CREATE exemplifies the convergence of clinically validated CAR architectures, optimized RNA designs, and targeted delivery technologies, combining deep expertise in clinical development, translational medicine, and regulatory execution. This efficient integration is designed to enhance the overall treatment landscape, aiming to address not just one but several critical health challenges across autoimmune diseases and cancer.